L-Alanine and L-Glutamine Supplementation in CKD Patients
High-dose parenteral L-glutamine should NOT be administered to critically ill CKD patients, and routine supplementation of L-alanine or L-glutamine is not recommended for stable non-dialysis CKD patients based on current evidence. 1
Critical Distinction: Critically Ill vs. Stable CKD Patients
For Critically Ill CKD Patients (AKI, AKI on CKD, or CKD with Kidney Failure)
Do NOT use high-dose parenteral glutamine. The 2024 ESPEN guideline provides Grade A evidence (100% consensus) against this practice 1. The landmark REDOX study demonstrated that high doses of alanyl-glutamine (whether intravenous or enteral) are harmful in critically ill patients with kidney failure, despite documented glutamine losses of approximately 1.2 g/day during continuous kidney replacement therapy. The MetaPlus trial corroborated these findings in critically ill populations.
Key pitfall: Earlier underpowered studies suggested benefit when pooled in meta-analyses, but the most recent high-quality evidence clearly shows harm. Always prioritize the REDOX study findings over older meta-analyses.
For Stable Non-Dialysis CKD Patients
The evidence for L-alanine and L-glutamine supplementation in stable CKD is limited and conflicting:
Potential Benefits (Limited Evidence)
- A 2022 proof-of-concept study 2 showed that a mixture containing essential amino acids (including glutamine and alanine) at 8 g/day for 6 months improved gut barrier dysfunction markers (decreased fecal calprotectin and zonulin) in stage 3b-4 CKD patients
- A small 2004 study 3 suggested that oral supplementation with selective amino acids (including L-glutamine) may slow progression in patients with creatinine clearance 15-24 mL/min on low-protein diets
Safety Concerns
- Acute kidney injury risk: A 2025 case report 4 documented AKI from tubular damage in a patient taking 18 grams daily of L-glutamine, likely due to increased ammonia production and toxicity
- Renal function changes: A 2010 study 5 in elderly individuals showed statistically significant (though not clinically significant) increases in serum urea nitrogen and creatinine, with a 13.3% decrease in estimated GFR after L-glutamine supplementation at 0.5 g/kg/day
- Impaired clearance: Chronic renal failure significantly reduces clearance of both alanyl-glutamine and glycyl-glutamine dipeptides 6
Practical Recommendations
For stable non-dialysis CKD patients:
- Do not routinely supplement L-alanine or L-glutamine as standalone interventions
- If considering amino acid supplementation, use only as part of a comprehensive nutritional strategy under specialist supervision
- Maximum safe dose if used: ≤0.5 g/kg/day of L-glutamine, with rigorous monitoring of renal function parameters
- Absolute contraindication: Doses ≥18 g/day in elderly patients or those with compromised kidney function 4
- Monitor serum urea nitrogen, creatinine, and eGFR closely if any supplementation is attempted
Focus instead on evidence-based nutritional management:
- Low-protein diet (0.6-0.8 g/kg/day) with adequate energy intake (>30 kcal/kg/day) 7
- Ensure sufficient intake of essential amino acids through dietary sources rather than isolated supplements
- Address gut barrier dysfunction through dietary quality and plant-based approaches 8
Critical monitoring if supplementation is attempted:
- Baseline and serial measurements of serum creatinine, urea nitrogen, and eGFR
- Watch for signs of ammonia toxicity (confusion, altered mental status)
- Discontinue immediately if eGFR decreases >25% or clinical deterioration occurs
The evidence does not support routine use of L-alanine or L-glutamine supplements in CKD patients, and the risk-benefit ratio is unfavorable, particularly given the potential for acute kidney injury and the strong evidence against use in critically ill patients with kidney dysfunction.